⭐ Novartis has sold its captive biomanufacturing facility in France to Seqens, a pharmaceutical ingredients firm.
⭐ Seqens plans to expand the facility and develop it into a contract development and manufacturing organization (CDMO).
⭐ This move will allow Novartis to focus on its core business and leverage Seqens’ expertise in contract manufacturing.
⭐ Seqens aims to provide services to the growing biopharmaceutical industry.
⭐ The sale is in line with Novartis’ strategy to streamline its manufacturing network and outsource non-core activities.
⭐ Seqens plans to expand the facility and develop it into a contract development and manufacturing organization (CDMO).
⭐ This move will allow Novartis to focus on its core business and leverage Seqens’ expertise in contract manufacturing.
⭐ Seqens aims to provide services to the growing biopharmaceutical industry.
⭐ The sale is in line with Novartis’ strategy to streamline its manufacturing network and outsource non-core activities.
📢 Novartis Sells French Biomanufacturing Facility Seqens to Expand and Revolutionize Industry
Introduction:
Novartis, a multinational pharmaceutical company, has sold its France-based Contract Development & Manufacturing Organization (CDMO) division to Seqens. This sale is part of Novartis’ strategy to streamline its global manufacturing network and focus on its core business areas.
Main points:
- Novartis has sold its France-based CDMO division to Seqens, a leading player in the pharmaceutical and fine chemicals industry.
- The sale includes the transfer of the manufacturing facilities, employees, and customer contracts of Novartis’ CDMO division.
- This divestment is part of Novartis’ ongoing efforts to optimize its manufacturing network and focus on its core business areas.
- Seqens intends to leverage the acquired CDMO capabilities to strengthen its position in the pharmaceutical market and expand its manufacturing capacity.
- The financial details of the transaction have not been disclosed.
Conclusion:
Novartis’ sale of its France-based CDMO division to Seqens is a strategic move to streamline its manufacturing network and prioritize its core business areas. Seqens, on the other hand, aims to enhance its presence in the pharmaceutical market and increase its manufacturing capacity through this acquisition. The financial details of the transaction have not been released.
